

- Brain natriuretic peptide. *See* B-type natriuretic peptide (BNP)
- Brainstem accessory optic system, 195
- Brainstem auditory evoked potentials (BAEPs), 223, 442e-3
- Brainstem disorders/lesions  
clinical features of, 2540t  
ischemia, 2577-2580f, 2578  
sensory abnormalities in, 161  
weakness in, 156
- Brainstem reflexes, 1774-1775, 1774f
- Brain tumors, **598**  
amnesia in, 183  
approach to the patient, 598  
clinical features of, 598, 598t  
germ cell tumors, 2264  
headache in, 107t, 108, 598  
imaging in, 440e-9f, 598  
intracranial hemorrhage in, 2583t, 2584  
metastatic, **604**  
diagnosis of, 604-605, 605f  
epidural. *See* Spinal cord compression, neoplastic  
increased intracranial pressure and, 1792  
leptomeningeal, 605, 606f  
sources of, 604, 604t  
treatment of, 605
- in neurofibromatosis type 1, 604-605. *See also* Neurofibromatosis type 1 (NF1)
- in neurofibromatosis type 2, 605. *See also* Neurofibromatosis type 2 (NF2)
- primary, **599**  
extrinsic "benign," **602**  
colloid cysts, 603  
craniopharyngiomas. *See* Craniopharyngiomas  
dermoid cysts, 603  
dysembryoplastic neuroepithelial tumors, 603  
epidermoid cysts, 603  
meningiomas. *See* Meningiomas  
pituitary tumors. *See* Pituitary tumors (adenomas)  
schwannomas, 602-603. *See also* Vestibular schwannoma (acoustic neuroma)  
genetic syndromes associated with, 599t  
intrinsic malignant  
astrocytomas. *See* Astrocytomas  
brainstem gliomas, 441e-39f, 601  
ependymoma, 441e-39f, 601  
gangliomas, 601  
gliosarcomas, 601  
medulloblastomas, 602  
oligodendroglioma, 600-601  
pineal region tumors, 602  
pleomorphic xanthoastrocytomas, 601  
primary central nervous system lymphoma. *See* Primary central nervous system lymphoma (PCNSL)  
pathogenesis of, 599  
treatment of, 598-599  
in tuberous sclerosis, 604. *See also* Tuberous sclerosis (Bourneville's disease)
- Branched-chain DNA (bdNA) tests, 150e-7-8, 1247, 1247t
- Branching enzyme deficiency (type IV glycogenosis), 462e-14
- Branchio-oto-renal (BOR) syndrome, 222t, 1855
- Branch retinal vein occlusion, 201
- Brazil, 13e-6, 13e-6f
- BRC (benign recurrent cholestasis), 284
- BRCA gene mutations  
in breast cancer, 523-524  
cancers associated with, 101e-6t  
early interventions in patients with, 450t  
epigenetic silencing of, 102e-7  
genetic testing for, 101e-6, 450t, 480, 523  
in ovarian cancer, 592  
in pancreatic cancer, 554  
synthetic lethality and, 102e-7  
variable expression of, 446
- Break-bone fever. *See* Dengue fever
- Breakpoint method, 150e-9
- Breast cancer, **523**  
biology of, 526  
carcinoma of unknown primary and, 120e-1, 120e-2t, 120e-3  
in contralateral breast, 531  
deaths from  
in 2014, 467t, 523  
by age group, 6e-2f  
by racial and ethnic group, 471t  
trends in, 469f, 470t  
diagnosis of, 524-526, 525f, 526f  
epidemiology of, 524  
epigenetic silencing in, 102e-7  
estrogen and progesterone receptor status of, 526, 528  
follow-up, 532, 532t  
gene expression profiles in, 448, 526  
genetic considerations in, 101e-2t, 101e-3, 101e-6t, 446, 447f, 523-524  
global considerations in, 524  
hereditary, 447, 450t. *See also* BRCA gene mutations  
histologic classification of, 528  
incidence of, 467t, 468, 468f, 471t, 523  
infections in, 484t  
lifetime risk of, 6e-1, 27t, 524  
male, 523, 532  
metastatic  
to bone, 119e-4  
bone marrow examination in, 81e-7f  
to CNS, 604, 604t, 606f, 2653, 2653f  
diagnosis of, 529  
to eye, 206  
to heart, 289e-2  
to liver, 553  
lymphadenopathy in, 408  
prognosis of, 529  
timing of, 529  
treatment of, 529-531  
noninvasive, 531-532  
oral contraceptives and, 2391t  
ovarian cancer and, 592  
paraneoplastic syndromes in  
endocrinologic, 609, 609t, 614t  
hematologic, 612, 612t  
neurologic, 618  
as perceived health problem, 6e-2f  
pleural effusion in, 474  
during pregnancy or lactation, 124e-1t, 124e-3-4, 124e-3t, 525-526  
prevention of  
lifestyle modifications for, 476  
pharmacologic, 478, 531  
prophylactic surgery for, 103e-3, 450t, 479  
tamoxifen for, 478  
prognosis of, 528, 528t  
radiation-induced, 103e-4, 524, 623  
recurrent, 103e-16, 528  
risk factors for  
alcohol use, 524, 2725  
diet, 476, 524  
hormone use, 524, 2383, 2384f  
obesity, 95e-5, 524  
screening for  
benefits of, 27, 28t, 480, 526  
in elderly, 84  
recommendations for high-risk women, 480, 526  
recommendations for normal-risk women, 29t, 480, 481t, 526  
second malignancies in survivors of, 623  
staging of, 526, 527t, 528  
subtypes of, 526  
treatment of, **526**  
ado-trastuzumab emtansine, 102e-4, 102e-5t, 103e-22  
biologic therapy, 103e-21, 103e-21t  
chemotherapy, 528-531, 529t  
hormone receptor-directed, 102e-7, 103e-15-16, 530, 530t  
HSCT, 139e-6, 531  
late consequences of, 622, 624t  
lymphedema after, 1654  
in metastatic disease, 529-530  
in postmenopausal women, 528-529, 529t  
in premenopausal women, 528, 529t  
radiation therapy, 527  
sentinel lymph node biopsy, 528  
in stage III disease, 531  
surgical, 526-528  
tamoxifen, 102e-7  
targeted chemotherapy, 102e-5t, 102e-6, 102e-16, 103e-19  
trastuzumab, 102e-4, 102e-5t, 102e-6, 102e-10, 103e-21, 103e-21t  
tumor growth rate measures in, 528  
tumor markers in, 473t, 526
- Breast development, 2379, 2379t
- Breast-feeding  
AED use during, 2559  
antibacterial therapy during, 936, 937t  
HIV transmission by, 50, 1223  
during SLE therapy, 2133  
water requirement during, 95e-1
- Breast mass  
benign, 526  
cyst, 525f, 526  
evaluation of, 524-526, 525f, 526f  
palpable, 524-525, 525f  
in pregnant or lactating woman, 124e-3, 525-526
- Breast milk jaundice, 2001
- Breast self-examination, 480, 481t, 526
- Breath sounds, 1662
- Brenner tumor, 592
- Brentuximab vedotin, 102e-4, 102e-5t, 103e-22
- Breslow thickness, 496
- BRIC (benign recurrent intrahepatic cholestasis), 284, 2003t, 2004, 2076
- Brill-Zinsser disease, 152e-5t, 1154, 1158
- Brim sign, 426e-2
- Brincidofovir (CMX-001), 215e-7, 261e-6
- Bristleworm sting, 2739, 2739f
- Brittle asthma, 1680
- Broadbent's sign, 1576
- Broad casts, urinary, 294
- Broca's aphasia, 177t, 178
- Broca's area, 177, 180f
- Brodalumab, 2177
- Brodie-Trendelenburg test, 1651f
- Bromides, 366, 2764t
- Bromocriptine  
for acromegaly, 2271  
adverse effects of, 1650, 2268  
overdosage/poisoning with, 473e-8t  
for prolactinoma, 2268  
for prolactin-secreting tumors, 103e-16  
for type 2 diabetes mellitus, 2415
- Bronchial artery embolization, 247
- Bronchial aspirate, 150e-4t
- Bronchial hygiene, 1696
- Bronchial neuroendocrine tumors (carcinoids), 269, 560t, 563-564
- Bronchiectasis, **1694**  
approach to the patient, 1695  
breath sounds in, 1662  
chest radiograph in, 308e-11f  
clinical features of, 1695  
clubbing/hypertrophic osteoarthropathy in, 250  
complications of, 1696  
CT in, 308e-3f, 308e-12f  
definition of, 1694  
diagnosis of, 1694t, 1695, 1695f  
epidemiology of, 1695  
etiology of, 1694-1695, 1695t  
global considerations in, 1695  
hemoptysis in, 245  
imaging in, 308e-11-12f, 1695, 1695f  
lung transplantation for, 320e-1t  
nontuberculous mycobacterial, 205e-8, 1129, 1130, 1694, 1696  
pathogenesis of, 1695  
prevention of, 1696  
prognosis of, 1696  
traction, 1695  
treatment of, 1696